Filtern
Volltext vorhanden
- ja (10)
Gehört zur Bibliographie
- ja (10)
Dokumenttyp
Sprache
- Englisch (10)
Schlagworte
- mitotane (2)
- ACTH (1)
- ALT (1)
- ATRX (1)
- Addisons disease (1)
- Adrenocortical Carcinoma (1)
- CRH stimulation test (1)
- CYP2B6 (1)
- CYP2W1 (1)
- Cushing's disease (1)
- Cushing’s syndrome (1)
- Graves disease (1)
- NOP10 (1)
- PPGL (1)
- SNP (1)
- TERT (1)
- adjuvant treatment (1)
- adrenal crisis (1)
- adrenal insufficiency (1)
- adrenal tumours (1)
- adrenocortical cancer (1)
- adrenocortical carcinoma (1)
- adrenocortical carcinoma (ACC) (1)
- adult patients (1)
- biomarker (1)
- circadian therapy (1)
- cortisol (1)
- diagnosis (1)
- ectopic (1)
- endogenous hypercortisolism (1)
- gene (1)
- glucocorticoid replacement regimens (1)
- haplotype (1)
- hashimotos-thyroiditis (1)
- high dose dexamethasone suppression test (1)
- hydrocortisone (1)
- hypopituitary patients (1)
- identical twins (1)
- liver resection (1)
- medicine (1)
- modified-release hydrocortisone (1)
- paraganglioma (1)
- pheochromocytoma (1)
- polyglandular autoimmune syndrome (1)
- polymorphism (1)
- population (1)
- predictive marker (1)
- premature mortality (1)
- prevalence (1)
- prognosis (1)
- prognostic biomarker (1)
- radiotherapy (RT) (1)
- recurrence (1)
- recurrence free survival (1)
- retrospective study (1)
- rheumatoid arthritis (1)
- short term (1)
- subjective health-status (1)
- survival analysis (1)
- susceptibility (1)
- telomeres (1)
- therapeutic management (1)
- timing (1)
Institut
- Medizinische Klinik und Poliklinik I (9)
- Comprehensive Cancer Center Mainfranken (4)
- Klinik und Poliklinik für Allgemein-, Viszeral-, Gefäß- und Kinderchirurgie (Chirurgische Klinik I) (2)
- Abteilung für Molekulare Innere Medizin (in der Medizinischen Klinik und Poliklinik II) (1)
- Klinik und Poliklinik für Strahlentherapie (1)
- Urologische Klinik und Poliklinik (1)
Background
International guidelines emphasise the role of radiotherapy (RT) for the management of advanced adrenocortical carcinoma (ACC). However, the evidence for this recommendation is very low.
Methods
We retrospectively analysed all patients who received RT for advanced ACC in five European centres since 2000. Primary endpoint: time to progression of the treated lesion (tTTP). Secondary endpoints: best objective response, progression-free survival (PFS), overall survival (OS), adverse events, and the establishment of predictive factors by Cox analyses.
Results
In total, 132 tumoural lesions of 80 patients were treated with conventional RT (cRT) of 50–60 Gy (n = 20) or 20–49 Gy (n = 69), stereotactic body RT of 35–50 Gy (SBRT) (n = 36), or brachytherapy of 12–25 Gy (BT) (n = 7). Best objective lesional response was complete (n = 6), partial (n = 52), stable disease (n = 60), progressive disease (n = 14). Median tTTP was 7.6 months (1.0–148.6). In comparison to cRT\(_{20-49Gy}\), tTTP was significantly longer for cRT\(_{50-60Gy}\) (multivariate adjusted HR 0.10; 95% CI 0.03–0.33; p < 0.001) and SBRT (HR 0.31; 95% CI 0.12–0.80; p = 0.016), but not for BT (HR 0.66; 95% CI 0.22–1.99; p = 0.46). Toxicity was generally mild and moderate with three grade 3 events. No convincing predictive factors could be established.
Conclusions
This largest published study on RT in advanced ACC provides clear evidence that RT is effective in ACC.